ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00413036

Public ClinicalTrials.gov record NCT00413036. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 6:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma

Study identification

NCT ID
NCT00413036
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Celgene
Industry
Enrollment
217 participants

Conditions and interventions

Interventions

  • lenalidomide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2006
Primary completion
Mar 31, 2011
Completion
Apr 30, 2011
Last update posted
Feb 28, 2017

2006 – 2011

United States locations

U.S. sites
20
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Northwest Alabama Cancer Center, PC Muscle Shoals Alabama 35661
Mayo Clinic Scottsdale Scottsdale Arizona 85259
Lalita Pandit, MD, Inc Fountain Valley California 92708
Access Clinical Research Rancho Mirage California 92270
Kaiser Permanente Medical Group San Diego California 92120
Pasco Hernando Oncology Associates Brooksville Florida 34613
Sylvester Cancer Center/ Univeristy of Miami Miami Florida 33136
Hematology Oncology Associates of Central Brevard Rockledge Florida 32955
Palm Beach Cancer Institute West Palm Beach Florida 33401
Cancer Care Center, Inc. New Albany Indiana 47150
Ochsner Clinic Foundation Baton Rouge Louisiana 70809
Michigan Hematology and Oncology Institute Southgate Michigan 48195
Mayo Clinic Rochester Minnesota 55905
University of Nebraska Omaha Nebraska 68198
Center for Cancer and Hematologic Disease Cherry Hill New Jersey 08003
Roswell Park Cancer Institute Buffalo New York 14263
Our Lady of Mercy Cancer Center The Bronx New York 10466
HIllman Cancer Center -UPMC Pittsburgh Pennsylvania 15232
Palmetto Hematology Oncology Spartanburg South Carolina 29303
Family Cancer Center Collierville Tennessee 38017

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00413036, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 28, 2017 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00413036 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →